Standout Papers
Citation Impact
Citing Papers
Ambrisentan for the Treatment of Pulmonary Arterial Hypertension
2008 Standout
Predicting Survival in Pulmonary Arterial Hypertension
2010 Standout
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
Bosentan Therapy in Patients With Eisenmenger Syndrome
2006
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
2014 Standout
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension
2009
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
2014 Standout
Tadalafil Therapy for Pulmonary Arterial Hypertension
2009 Standout
Valsartan
1997
A meta-analysis of trials of pulmonary hypertension: A clinical condition looking for drugs and research methodology
2007
Long-Term Bosentan in Chronic Thromboembolic Pulmonary Hypertension
2006
Significance of angiotensin type 1 receptor blockade: why are angiotensin II receptor blockers different?
1999
Idiopathic pulmonary fibrosis
2017 Standout
Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension
2006
Effects of the oral endothelin-receptorantagonist bosentan on echocardiographicand doppler measures in patients with pulmonary arterial hypertension
2003
The Clinical Sequelae of Intravascular Hemolysis and Extracellular Plasma Hemoglobin
2005 Standout
Medical Therapy For Pulmonary Arterial Hypertension
2004
Clinical Efficacy of Sitaxsentan, an Endothelin-A Receptor Antagonist, in Patients With Pulmonary Arterial Hypertension
2002
Medical Therapy for Pulmonary Arterial Hypertension
2007
Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer
2015
Treatment of Pulmonary Arterial Hypertension
2004 Standout
Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: Results of the BREATHE-5 open-label extension study
2007
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
2011 Standout
Pulmonary Arterial Hypertension
2009
Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials
2007
Valsartan in heart failure patients previously untreated with an ACE inhibitor
1998
BUILD-1: A Randomized Placebo-controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis
2007
Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension
2008
Definitions and Diagnosis of Pulmonary Hypertension
2013 Standout
Antithrombotic Therapy for VTE Disease
2016 Standout
Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards
2014
Updated Clinical Classification of Pulmonary Hypertension
2009 Standout
Advances in the treatment of secondary pulmonary hypertension
2003
Systemic sclerosis associated pulmonary hypertension: improved survival in the current era
2005
Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents
2017 Standout
Systemic sclerosis
2017 Standout
Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: An observational study
2011
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009 Standout
Clinical classification of pulmonary hypertension
2004 Standout
Survival with first-line bosentan in patients with primary pulmonary hypertension
2005
Six-Minute Walk Test and Health Status Assessment in Sarcoidosis
2007
Pulmonary Arterial Hypertension
2006
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
2011 Standout
Scleroderma
2009 Standout
Primary pulmonary hypertension
2003
Management of Pulmonary Arterial Hypertension Associated with Congenital Systemic-to-Pulmonary Shunts and Eisenmenger???s Syndrome
2008
Sarcoidosis
2013 Standout
2007 Guidelines for the Management of Arterial Hypertension
2007 Standout
Bosentan Therapy for Inoperable Chronic Thromboembolic Pulmonary Hypertension
2005
Six-minute walk distance as parameter of functional outcome after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension
2007
Effects of Long-Term Bosentan in Children With Pulmonary Arterial Hypertension
2005
Initial experience with bosentan therapy in patients considered ineligible for heart transplantation because of severe pulmonary hypertension
2006
Pathobiology of pulmonary arterial hypertension
2002
Targeting the endothelin axis in scleroderma renal crisis: rationale and feasibility
2013
Air Pollution and Heart Rate Variability
2008
The Current Treatment of Pulmonary Arterial Hypertension
2006
Diagnosis and Assessment of Pulmonary Arterial Hypertension
2009
Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2
2004
Pharmacologic Therapy for Pulmonary Arterial Hypertension in Adults
2014
Bladder cancer
2016 Standout
Hemodynamic Observations in Two Pulmonary Hypertensive Patients Changing Treatment From Inhaled Iloprost to the Oral Endothelin-Antagonist Bosentan
2005
Bosentan Therapy for Pulmonary Arterial Hypertension
2002 Standout
Updated Clinical Classification of Pulmonary Hypertension
2013 Standout
Effects of Iron Supplementation and Depletion on Hypoxic Pulmonary Hypertension
2009 StandoutNobel
Sickle-cell disease
2010 Standout
Ambrisentan Therapy for Pulmonary Arterial Hypertension
2005
A meta-analysis of randomized controlled trials in pulmonary arterial hypertension
2008
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
2012 Standout
Pulmonary–Hepatic vascular Disorders (PHD)
2004
Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach
2003
Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial
2008
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension
2015 Standout
Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol
2005
Helicobacter pylori Eradication to Prevent Gastric Cancer in a High-Risk Region of China
2004 Standout
Idiopathic pulmonary fibrosis
2011 Standout
Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension
2005
Transition‐Metal‐Catalyzed Direct Arylation of (Hetero)Arenes by CH Bond Cleavage
2009 Standout
Transient Receptor Potential Cation Channels in Disease
2007 Standout
The increase in pulmonary arterial pressure caused by hypoxia depends on iron status
2008 StandoutNobel
Portopulmonary hypertension and hepatopulmonary syndrome
2004
Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
2013
Electrocardiographic and Hemodynamic Effects of a Multicomponent Dietary Supplement Containing Ephedra and Caffeine
2004
Macitentan: entry-into-humans study with a new endothelin receptor antagonist
2011
Radical oxygen species production induced by advanced oxidation protein products predicts clinical evolution and response to treatment in systemic sclerosis
2007
Guidelines for the Echocardiographic Assessment of the Right Heart in Adults: A Report from the American Society of Echocardiography
2010 Standout
Introduction
2004
Complications of Right Heart Catheterization Procedures in Patients With Pulmonary Hypertension in Experienced Centers
2006
Sitaxsentan Therapy for Pulmonary Arterial Hypertension
2003
Chemokine RANTES in Severe Pulmonary Arterial Hypertension
2002
Bosentan Inhibits Transient Receptor Potential Channel Expression in Pulmonary Vascular Myocytes
2004
Bosentan for the Treatment of Human Immunodeficiency Virus–associated Pulmonary Arterial Hypertension
2004
BUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis
2011
Randomized Study of Adding Inhaled Iloprost to Existing Bosentan in Pulmonary Arterial Hypertension
2006
Pulmonary Arterial Hypertension in France
2006 Standout
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
2005 Standout
Microalbuminuria Reduction With Valsartan in Patients With Type 2 Diabetes Mellitus
2002
Markers of Inflammation and Cardiovascular Disease
2003 Standout
Diabetic Nephropathy: Diagnosis, Prevention, and Treatment
2005 Standout
Selective Upregulation of Endothelin B Receptor Gene Expression in Severe Pulmonary Hypertension
2002
Pulmonary Vascular Disease in Adults With Congenital Heart Disease
2007
Diversity‐Oriented Syntheses by Combining CuAAC and Stereoselective INCIC Reactions with Peptides
2017 StandoutNobel
ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease
2008 Standout
Pulmonary Arterial Hypertension
2006
ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease: Executive Summary
2008 Standout
Long-term intravenous epoprostenol infusion in primary pulmonary hypertension
2002 Standout
Indications for Cardiac Catheterization and Intervention in Pediatric Cardiac Disease
2011 Standout
Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension
2011 Standout
Right Ventricular Function in Cardiovascular Disease, Part II
2008
Warfarin plus Aspirin after Myocardial Infarction or the Acute Coronary Syndrome: Meta-Analysis with Estimates of Risk and Benefit
2005
Chronic Thromboembolic Pulmonary Hypertension
2006 Standout
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2020 Standout
Right Ventricular Function in Cardiovascular Disease, Part I
2008 Standout
Particulate Matter Air Pollution and Cardiovascular Disease
2010 Standout
Evaluation and Management of the Patient with Pulmonary Arterial Hypertension
2005
Efficacy and Safety of the Angiotensin Receptor Blocker Valsartan in Children With Hypertension Aged 1 to 5 Years
2008
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension
2009 Standout
Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival
2003
Works of Frédéric Bodin being referenced
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study
2001 Standout
Influence of Mild Liver Impairment on the Pharmacokinetics and Metabolism of Bosentan, a Dual Endothelin Receptor Antagonist
2003
Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: A comparative study of the efficacy and safety against amlodipine*
1996
Complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension
2002
In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide
2002
Influence of Food Intake and Formulation on the Pharmacokinetics and Metabolism of Bosentan, a Dual Endothelin Receptor Antagonist
2002